Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294629 | 0.87 | TBXAS1 (0.50) | TBXAS1ACHEEGLN3PRKCIKDM4E | |
| SCHEMBL11011577 | 0.84 | ACHE (0.60) | TBXAS1ACHEEGLN3PRKCICYP3A4 | |
| SCHEMBL18402589 | 0.84 | TBXAS1 (0.61) | TBXAS1ACHEEGLN3PRKCIKDM4E | |
| SCHEMBL1308861 | 0.83 | TBXAS1 (0.48) | TBXAS1ACHEEGLN3PRKCICYP11B1 | |
| SCHEMBL28790059 | 0.83 | TBXAS1 (0.48) | TBXAS1ACHEEGLN3PRKCICYP11B1 | |
| SCHEMBL8699805 | 0.82 | ACHE (0.59) | TBXAS1ACHEEGLN3CYP3A4 | |
| SCHEMBL10294008 | 0.82 | TBXAS1 (0.44) | TBXAS1ACHEEGLN3PRKCICYP11B1 | |
| SCHEMBL12190582 | 0.82 | TBXAS1 (0.44) | TBXAS1ACHEEGLN3PRKCITSHR | |
| SCHEMBL20834956 | 0.81 | TBXAS1 (0.72) | TBXAS1ACHEKDM4E | |
| SCHEMBL4758301 | 0.81 | TBXAS1 (0.50) | TBXAS1ACHEEGLN3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | claimed |
| EP-3960726-A9 | AMINE CATIONIC LIPIDS AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3960726-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3597644-B1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-2768958-B1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-05-18 | — | — | US | disclosed |
| US-9549983-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | TBXAS1 290/4885ACHE 2310/4885EGLN3 1050/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | TBXAS1 252/4885ACHE 521/4885EGLN3 3381/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | TBXAS1 3814/4885ACHE 4115/4885EGLN3 2674/4885 |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | TBXAS1 1994/4885ACHE 4620/4885EGLN3 1695/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | TBXAS1 2471/4885ACHE 3506/4885EGLN3 4802/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | TBXAS1 290/4885ACHE 2310/4885EGLN3 1050/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | TBXAS1 1834/4885ACHE 2757/4885EGLN3 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.